In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

Excerpts from recent editorials in the United States and abroad: ___ Jan. 26 The Washington Post on Trump's “energy emergency” Oil and gas production in the United States is hitting record highs, ...

"And we're not used to having somebody without a career at stake in the room at a senior level," said Hudson.

A law that coaxed companies to lower the price of drugs came with a little-known consequence: smaller discounts for ...

It took another year for the FDA to grant interchangeability status to Rezvoglar, meaning it can be substituted at the pharmacy for Lantus, the brand name insulin glargine, without needing a separate ...

Sanofi-Synthélabo is known for creating meningitis treatment, Menactra, diabetes treatment Lantus, colorectal cancer drug Eloxatin, and lung, prostate and breast cancer drug Taxorete. While this ...

If approved as a biosimilar, Semglee will be established as the first direct competitor of Lantus, giving providers an alternative treatment option that they can feel confident in prescribing.